Marc Mansour Selected Research

2-Methyl-4-chlorophenoxyacetic Acid (MCPA)

1/2016	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
1/2014	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Mansour Research Topics

Disease

18	Neoplasms (Cancer) 01/2020 - 06/2006
4	Communicable Diseases (Infectious Diseases) 01/2020 - 08/2010
4	Prostatic Neoplasms (Prostate Cancer) 01/2014 - 07/2012
2	Sepsis (Septicemia) 01/2021 - 01/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2017 - 08/2011
2	Ovarian Neoplasms (Ovarian Cancer) 08/2015 - 04/2010
2	Injection Site Reaction 01/2014 - 08/2012
2	Hypoxia (Hypoxemia) 08/2004 - 02/2002
1	Malaria 01/2020
1	Persistent Infection 01/2020
1	Immune Complex Diseases (Immune Complex Disease) 01/2018
1	Cyanosis 01/2018
1	Genomic Instability 11/2017
1	Anthrax 01/2017
1	Human Influenza (Influenza) 01/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2011
1	Hepatitis B 10/2010
1	Carcinoma (Carcinomatosis) 04/2010
1	Whooping Cough (Pertussis) 10/2007
1	Diphtheria 10/2007
1	Tetanus 10/2007
1	Infections 10/2007
1	Melanoma (Melanoma, Malignant) 04/2007
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2006

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2020 - 06/2006
15	Peptides (Polypeptides)IBA 01/2021 - 06/2006
9	AntigensIBA 01/2018 - 04/2007
7	Cancer VaccinesIBA 01/2016 - 04/2010
5	EmulsionsIBA 06/2016 - 06/2006
4	DPX-0907IBA 01/2014 - 04/2010
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2014 - 06/2007
3	Proteins (Proteins, Gene)FDA Link 11/2017 - 06/2006
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 01/2014
3	Protein Subunit VaccinesIBA 01/2014 - 04/2010
3	Liposomes (Liposome)IBA 10/2007 - 06/2006
2	LigandsIBA 01/2021 - 01/2020
2	Immunologic Factors (Immunomodulators)IBA 01/2021 - 01/2020
2	Malaria VaccinesIBA 01/2020 - 01/2020
2	Monoclonal AntibodiesIBA 01/2020 - 01/2020
2	2-Methyl-4-chlorophenoxyacetic Acid (MCPA)IBA 01/2016 - 01/2014
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	AntibodiesIBA 01/2021
1	Vaccine AdjuvantsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2018
1	aluminum sulfate (alum)IBA 01/2018
1	Complement C3 (C3 Complement)IBA 01/2018
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2018
1	Anthrax Vaccines (Vaccines, Anthrax)IBA 01/2017
1	Poly I-CIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	SurvivinIBA 08/2015
1	Biomarkers (Surrogate Marker)IBA 01/2015
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2014
1	CytokinesIBA 01/2013
1	afimoxifene (hydroxytamoxifen)IBA 08/2011
1	Messenger RNA (mRNA)IBA 08/2011
1	Transcription Factors (Transcription Factor)IBA 08/2011
1	Recombinant ProteinsIBA 08/2010
1	Nucleic Acid-Based VaccinesIBA 08/2010
1	Bacterial AntigensIBA 08/2010
1	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 10/2007
1	Biological ProductsIBA 06/2007
1	Molecular Chaperones (Chaperone, Molecular)IBA 02/2002

Therapy/Procedure

7	Immunotherapy 01/2020 - 06/2007
4	Therapeutics 01/2020 - 04/2007
1	Ligation 01/2021
1	Punctures 01/2021
1	Drug Therapy (Chemotherapy) 08/2011
1	Heterologous Transplantation (Xenotransplantation) 08/2004